Business Context and Reporting Period
Company: Bovie Medical Corporation (Note: Metadata referenced "Apyx Medical Corp," but the filing text identifies the registrant as Bovie Medical Corporation).
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Bovie Medical Corporation manufactures and markets electrosurgical devices, including generators, accessories, cauteries, and medical lighting. Operations are divided into three product lines: electrosurgical products, battery-operated cauteries, and other products (nerve locators, lighting). The company operates facilities in St. Petersburg, Florida, and Windsor, Canada.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Sales (Revenue) | $7,295,793 | $20,958,672 | $21,602,061 |
| Gross Profit | $3,233,369 | $8,719,747 | $8,659,160 |
| Gross Margin | 44.3% | 41.6% | 40.1% |
| Net Income | $365,890 | $1,793,021 | $2,119,813 |
| Operating Cash Flow (9mo) | $1,430,001 (2008) vs $972,681 (2007) | ||
| Cash and Equivalents | $4,083,906 (Sep 30, 2008) | ||
| Working Capital | ~$7.5 million (Sep 30, 2008) | ||
| Debt (Line of Credit) | $2,850,000 (Current Liability) |
Material Changes vs. Prior Period
- Revenue Decline: Sales for the nine months ended September 30, 2008, decreased by 3.0% ($643,000) compared to the prior year. Domestic sales fell 6.1% due to lower OEM generator sales, while international sales increased 14.8%.
- Profitability: Net income for the nine-month period decreased 15.4% to $1.79 million. This decline is largely attributed to the absence of a $1.495 million "Gain on cancellation of agreement" recorded in the same period of 2007 (related to a settlement with Boston Scientific).
- Expense Increases:
- R&D: Increased 16.0% to $1.43 million due to development of new products (MEG, Polarian, SEER).
- Professional Services: Increased 9.5% to $667,000, driven by legal costs associated with the Erbe USA lawsuit.
- SG&A: Increased 7.7% to $3.22 million due to European channel expansion and higher commissions.
- Capital Expenditures: Investing cash outflows surged to $3.9 million (vs. $1.5 million in 2007) primarily due to the purchase of a new facility in Largo, Florida, for $3.0 million.
- Debt: The company utilized a $2.85 million line of credit to fund the facility purchase, a new liability not present in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic regarding new proprietary product development to reduce dependence on lower-margin OEM business.
- Recent Milestones:
- Received CE Mark for the SEER tissue resection device (liver oncology).
- Filed 510(k) pre-notification for SEER with the FDA.
- Received FDA 510(k) clearance for the ICON GP generator.
- Financing: The company anticipates closing a $4.0 million Industrial Revenue Bond in November 2008 to refinance the line of credit used for the new facility, which would shift the liability from current to non-current.
- Risks and Contingencies:
- Legal Proceedings: A civil action by Erbe USA, Inc. alleges a newly hired employee misappropriated trade secrets. The case is stayed pending discovery; exposure is currently indeterminable.
- Customer Concentration: The ten largest customers accounted for 69% of net revenues in the first nine months of 2008.
- Lease Obligations: Relocation to the new facility in 2009 may trigger a lease termination expense/liability for the current St. Petersburg facility (estimated net remaining lease rentals ~$780,000).
Investor Verification Checklist
- Refinancing Status: Verify the closing of the anticipated $4.0 million Industrial Revenue Bond to confirm the reduction of current liabilities.
- Legal Exposure: Monitor the status of the Erbe USA, Inc. lawsuit for potential financial impact or operational disruption.
- Product Launches: Track the commercialization and revenue contribution of the SEER device and Polarian vessel sealing instruments following regulatory clearances.
- Inventory Levels: Review inventory turnover given the increase in raw materials and work-in-process inventory ($5.44 million total) relative to the slight revenue decline.
- Customer Concentration: Assess the stability of the top 10 customers who represent nearly 70% of revenue.